CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients.

BACKGROUND The membrane cofactor protein CD46 represents a complement inhibitor, which protects autologous cells from complement - mediated cytotoxicity. CD46 may exhibit the potential to protect tumor cells from the immune responses of the host. The present study aimed to evaluate the prognostic significance of CD46 expression in ovarian cancers. MATERIALS AND METHODS The analyses were performed on 73 ovarian cancer samples. Immunohistochemical reactions were performed on paraffin sections of tumors using monoclonal antibodies directed against CD46. The immunohistochemical reactions and the clinical observations results were subjected to statistical analysis. RESULTS Expression of CD46 was demonstrated in 60% of primary laparotomy cases and in 70% secondary cytoreduction cases. Kaplan-Meier analysis showed that a significantly shorter revival-free time was linked to cases with CD46 expression at PL (p= 0.01). CONCLUSION Ovarian cancers manifest CD46 expression that is linked to a less favourable prognosis.

[1]  S. Meri,et al.  Ascitic complement system in ovarian cancer , 2005, British Journal of Cancer.

[2]  J. Robertson,et al.  Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer , 2004, International journal of cancer.

[3]  Z. Fishelson,et al.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. , 2003, Molecular immunology.

[4]  John D Lambris,et al.  Role of Membrane Cofactor Protein (CD46) in Regulation of C4b and C3b Deposited on Cells1 , 2002, The Journal of Immunology.

[5]  J. Berek,et al.  Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.

[6]  M. Daha,et al.  A Possible Role of CD46 for the Protection In Vivo of Human Renal Tumor Cells from Complement-Mediated Damage , 2000, Laboratory Investigation.

[7]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[8]  F. Akiyama,et al.  Toward the development of a universal grading system for ovarian epithelial carcinoma , 1998, Cancer.

[9]  C. Holmes,et al.  Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. , 1997, The American journal of pathology.

[10]  S. Meri,et al.  Complement‐regulatory proteins in ovarian malignancies , 1997, International journal of cancer.

[11]  P. Huettner,et al.  Human complement regulator expression by the normal female reproductive tract , 1996, The Anatomical record.

[12]  A. Dalmasso,et al.  Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). , 1996, The American journal of pathology.